Psychedelics

2020-09-23 PSW Editor

Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.

2020-09-23 PSW Editor

Mind Cure's organic Moonbeam mushroom products are now eligible for sale in Canada.

2020-09-23 PSW Editor

Compass Pathways has closed its IPO financing, raising $146.6 million via the sale of 8,625,000 American Depository Shares.

2020-09-22 PSW Editor

PharmaDrug will assume control of its first Super Smart psychedelics store on October 1st.

2020-09-22 Jeff Nielson

MindMed stock has spiked higher by over 30%, on big volume. New investor focus on the deepest clinical research program in the industry.

2020-09-22 Jeff Nielson

IPO fever is sweeping through the psychedelics space.

2020-09-22 Jeff Nielson

Psychedelic stock warrants that are currently out of the money COULD produce big returns for investors.

2020-09-21 PSW Editor

2020-09-21 PSW Editor

Numinus warrants have an exercise price of CAD$0.35 and are valid until September 10, 2022.

2020-09-21 PSW Editor

MindMed Inc has applied to up-list on the NASDAQ.

2020-09-21 PSW Editor

Revive's corporate update centers on psilocybin research on a new delivery system and addiction treatment.

2020-09-20 Jeff Nielson

The road to psychedelic drug success leads through functional mushrooms.

2020-09-19 PSW Editor

Canada stands out as the premier destination for psychedelic drug companies.

2020-09-18 PSW Editor

Compass Pathways has upsized its IPO financing to $127.5 million, at an offering price of $17.00 per American Depositiry Share (ADS).

2020-09-18 Jeff Nielson

A $225 billion treatment market is badly in need of new therapies. Here is the roadmap for investors to capitalize on this opportunity.